The Endocrine Society has officially announced that Rebecca Reynolds, MD, PhD, has been selected as the recipient of the 2026 International Excellence in Endocrinology Laureate Award, a distinction that recognizes her pioneering contributions to the field of metabolic medicine and her profound impact on global maternal-fetal health. Dr. Reynolds, who serves as the Personal Chair of Metabolic Medicine and Dean International at the University of Edinburgh’s College of Medicine and Veterinary Medicine, has spent her career investigating the intricate endocrine pathways that govern pregnancy. Her work has fundamentally altered the clinical understanding of how a mother’s metabolic environment during gestation can dictate the long-term health trajectory of her offspring. By bridging the gap between laboratory discovery and clinical application, Reynolds has provided the scientific community with a clearer lens through which to view the "stress test" of pregnancy and its enduring consequences for public health.
A Legacy of Excellence in Metabolic Medicine
The International Excellence in Endocrinology Award is among the highest honors bestowed by the Endocrine Society, an organization representing over 18,000 scientists and clinicians worldwide. Established to recognize individuals who have made exceptional contributions to the field of endocrinology in a global context, the award highlights Dr. Reynolds’ dual role as a high-impact researcher and a leader in international medical policy. Her selection for the 2026 cycle underscores the growing recognition of women’s health as a critical, yet historically underfunded, pillar of endocrine research.
At the University of Edinburgh, Dr. Reynolds has led multi-disciplinary teams to explore the mechanisms of fetal programming—the process by which the environment in the womb influences the development of chronic diseases later in life, such as type 2 diabetes, obesity, and cardiovascular disease. Her research has specifically focused on the role of glucocorticoids and other metabolic markers in mediating these effects. By identifying the cardiometabolic risks associated with maternal obesity and gestational diabetes, she has paved the way for more targeted interventions that protect both the mother and the developing child.
The "Stress Test" of Pregnancy: A New Clinical Paradigm
One of the most significant conceptual contributions Dr. Reynolds has made to the field is the framing of pregnancy as a physiological "stress test." During gestation, a woman’s body undergoes massive endocrine and metabolic shifts. For many, these changes can unmask underlying predispositions to metabolic dysfunction that might not have appeared until much later in life. Dr. Reynolds’ research suggests that complications such as gestational diabetes or preeclampsia are not merely transient issues of pregnancy but are early warning signs of future chronic illness.
This perspective has shifted the focus of postpartum care. Rather than viewing the end of pregnancy as the conclusion of a medical episode, Reynolds argues that it should be seen as the beginning of a lifelong monitoring process for women’s metabolic health. In her discussions regarding the award, Reynolds noted that while women represent half the global population, research into their specific physiological needs continues to lag behind that of men. Her work serves as a corrective to this disparity, providing robust evidence that maternal health is the bedrock of generational health.
Chronology of Research and Global Policy Impact
The trajectory of Dr. Reynolds’ career reflects a consistent commitment to translating complex science into actionable health policy. After completing her PhD, which ignited her fascination with how events in utero shape long-term outcomes, she climbed the academic ranks at the University of Edinburgh, one of the world’s leading centers for medical research.
Throughout the 2010s and into the 2020s, her findings began to permeate international clinical guidelines. Her research on maternal obesity and its endocrine implications directly informed the Royal College of Obstetricians and Gynaecologists (RCOG) guidelines, which are used by practitioners across the United Kingdom and the Commonwealth. Furthermore, her influence reached the Scottish Diabetes Prevention Programme, where her data helped shape strategies to mitigate the rising tide of type 2 diabetes through early intervention during the childbearing years.
Perhaps most notably, Reynolds’ impact has been felt in regions with limited healthcare infrastructure. She was a key contributor to the Obstetric Ultrasound Guideline for Malawi in 2021. This work is particularly significant because it applies high-level metabolic research to the practical realities of low-resource settings, ensuring that the benefits of endocrine science are not confined to wealthy nations. By helping to standardize obstetric care in Malawi, Reynolds has demonstrated that international excellence involves a commitment to global equity in health outcomes.
Supporting Data: The Global Burden of Maternal Metabolic Disease
To understand the scale of Dr. Reynolds’ impact, one must look at the current data regarding maternal health. According to the World Health Organization (WHO), the prevalence of obesity among pregnant women has reached epidemic proportions in many parts of the world. In the United Kingdom and the United States, it is estimated that nearly 20–25% of pregnant women are classified as obese at the start of their pregnancy.
Maternal obesity is linked to a higher risk of gestational diabetes mellitus (GDM), which affects approximately 14% of pregnancies globally. GDM not only increases the risk of delivery complications but also significantly raises the likelihood that the mother will develop type 2 diabetes within five to ten years after delivery. Furthermore, children born to mothers with poorly managed metabolic conditions are at a higher risk of childhood obesity and early-onset metabolic syndrome.
Dr. Reynolds’ work in identifying the endocrine markers that predict these outcomes has provided clinicians with the tools to intervene earlier. Her participation in clinical trials has tested the efficacy of metformin and lifestyle interventions in pregnant populations, contributing to a body of evidence that helps refine the standard of care for millions of women annually.
Official Responses and Peer Recognition
The announcement of the Laureate Award has been met with widespread acclaim from the international scientific community. Professor Ruth Andrew, PhD, Chair of Pharmaceutical Endocrinology and Director of the Edinburgh CRF MS Core, who nominated Reynolds for the award, emphasized the social importance of her research.
"Rebecca’s work has significant impact for women and children’s healthcare, particularly benefiting those living with poor healthcare infrastructure and challenging socioeconomic circumstances," Professor Andrew stated. This sentiment is echoed by many in the field who view Reynolds as a champion for the underserved.
Dr. Reynolds herself expressed surprise and gratitude upon receiving the news. She credited her success to the collaborative nature of her research and the participation of the patients who have contributed to her studies over the decades. "The award would not be possible without all the amazing people and patients that I have worked with," she remarked, highlighting the human element that drives her scientific inquiry.
Broader Implications for the Future of Endocrinology
The recognition of Dr. Reynolds by the Endocrine Society signals a broader shift in the priorities of the medical community. For decades, endocrinology focused heavily on established diseases like thyroid disorders or adrenal insufficiency. While these remains vital, the 2026 Laureate Award highlights the rising importance of "preventative endocrinology"—the study of how hormonal environments in early life can prevent disease decades before it manifests.
As the Dean International at Edinburgh, Reynolds is also shaping the next generation of scientists. Her leadership encourages a global perspective on medical education, fostering partnerships between European institutions and those in the Global South. This internationalism is essential for tackling the global rise in metabolic diseases, which do not respect national borders.
Furthermore, Reynolds’ work highlights the "funding gap" in women’s health. By winning this prestigious award, she brings much-needed visibility to the fact that pregnancy research is not just about the nine months of gestation, but about the long-term health of the entire population. Her advocacy for increased funding and better-designed clinical trials for women is expected to be a central theme of her Laureate address at ENDO 2026.
Beyond the Bench: A Holistic Approach to Science
Despite the demanding nature of her roles as a researcher, clinician, and dean, Dr. Reynolds maintains a balanced life that informs her professional perspective. She is a qualified Iyengar yoga teacher and practitioner, a discipline that emphasizes precision and alignment—qualities that are equally applicable to the rigors of metabolic research.
Additionally, she is an avid hillwalker in the Scottish Highlands. She is close to completing the "Munro bagging" challenge, which involves climbing all 282 Scottish mountains over 3,000 feet. Reynolds has noted that these periods of physical exertion and solitude in nature are often when she finds the most clarity for her research. "Both yoga and walking are refreshing and energizing, and sometimes I get my best ideas when I’m out walking," she shared. This holistic approach to life reflects the "whole-body" perspective she takes in her medical research, looking at the person behind the patient and the environment behind the illness.
Conclusion
As the Endocrine Society prepares for its 2026 conference, the spotlight on Rebecca Reynolds, MD, PhD, serves as a reminder of the power of dedicated, patient-centered research. Her work has not only unraveled the complex hormonal dance between mother and child but has also provided a roadmap for improving global health through the lens of pregnancy. By identifying the "stress test" of the womb, Dr. Reynolds has given the medical world the tools to build a healthier future, one generation at a time. Her receipt of the International Excellence in Endocrinology Laureate Award is a fitting tribute to a career spent at the intersection of science, policy, and compassionate care.